OCS vs. ORGO, BMEA, MRNS, IGMS, NATR, QURE, ANAB, CMPS, IMNM, and GRCL
Should you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Organogenesis (ORGO), Biomea Fusion (BMEA), Marinus Pharmaceuticals (MRNS), IGM Biosciences (IGMS), Nature's Sunshine Products (NATR), uniQure (QURE), AnaptysBio (ANAB), COMPASS Pathways (CMPS), Immunome (IMNM), and Gracell Biotechnologies (GRCL). These companies are all part of the "pharmaceutical preparations" industry.
Organogenesis (NASDAQ:ORGO) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, profitability, risk and institutional ownership.
Organogenesis has higher revenue and earnings than Oculis.
In the previous week, Organogenesis had 1 more articles in the media than Oculis. MarketBeat recorded 3 mentions for Organogenesis and 2 mentions for Oculis. Organogenesis' average media sentiment score of 1.36 beat Oculis' score of 1.29 indicating that Oculis is being referred to more favorably in the news media.
Organogenesis received 82 more outperform votes than Oculis when rated by MarketBeat users. However, 78.57% of users gave Oculis an outperform vote while only 65.49% of users gave Organogenesis an outperform vote.
39.5% of Organogenesis shares are owned by institutional investors. Comparatively, 14.3% of Oculis shares are owned by institutional investors. 34.0% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Organogenesis has a net margin of 2.90% compared to Organogenesis' net margin of 0.00%. Oculis' return on equity of 4.83% beat Organogenesis' return on equity.
Organogenesis currently has a consensus target price of $3.75, suggesting a potential upside of 37.36%. Oculis has a consensus target price of $34.00, suggesting a potential upside of 240.34%. Given Organogenesis' stronger consensus rating and higher possible upside, analysts clearly believe Oculis is more favorable than Organogenesis.
Summary
Organogenesis beats Oculis on 9 of the 15 factors compared between the two stocks.
Get Oculis News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools